More To Regeneron Pipeline Than Initially Meets Wall Street’s Eye
Executive Summary
Behind blockbuster seller Eylea and blockbuster hopeful PCSK9 inhibitor Praluent, Regeneron boasts a pipeline of 15 clinical candidates derived from its VelocImmune technology platform. Leading the next wave are sarilumab for rheumatoid arthritis and dupilumab for allergic indications, both partnered with Sanofi.
You may also be interested in...
Regeneron Confident In Relationship With Sanofi After Viehbacher’s Departure
Biotech and French partner remain on track to file PCSK9 inhibitor alirocumab this quarter in U.S. and EU; meanwhile, Eylea continues strong sales growth – but launch in second indication, diabetic macular edema, is slow.
Cosmetic And Personal Care Trademark Review: 16 April
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Health And Wellness Weekly Trademarks Review: 16 April
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.